According to Mark Cuban, the primary driver behind high drug prices in the US is not brand manufacturers but pharmacy benefit managers (PBMs), who manipulate pricing structures and enforce strict non-disclosure agreements in contracts (Source: Mark Cuban, Twitter, May 12, 2025). This revelation is significant for trading as it highlights regulatory risks and potential disruptions in the healthcare sector, which could influence related healthcare tokens and blockchain projects focused on pharmaceutical supply chains. Cuban’s comments may also drive investor interest towards decentralized, transparent solutions in the crypto market, particularly those addressing pricing opacity and middleman inefficiencies.